Endocannabinoids anandamide and its cannabinoid receptors in liver fibrosis after murine schistosomiasis

This study examined endogenous carmabinoid （ECB）-anandamide （AEA） and its cannabinoid receptors （CBR） in mice liver with the development ofschistosomajaponicum. Mice were infected with schistosoma by means of pasting the cercaria onto their abdomens. Liver fibrosis was pathologically confirmed nine weeks after the infection. High performance liquid chromatography （HPLC） was employed to determine the concentration of AEA in the plasma of mice. Immunofluo-rescence was used to detect the expression of CBR1 and CBR2 in liver tissue. Morphological examination showed typical pathological changes, with worm tubercles of schistosoma deposited in the liver tissue, fibrosis around the worm tubercles and infiltration or soakage of inflammatory cells. Also, CBR1 and CBR2 were present in hepatocytes and hepatic sinusoids of the two groups, but they were obviously enhanced in the schistosoma-infected mice. However, the average optical density of CBR1 in the negative control and fibrosis group was 13.28±7.32 and 30.55±7.78, and CBR2 were 28.13±6.42 and 52.29±4.24 （P〈0.05）. The levels of AEA in the fibrosis group were significantly increased as compared with those of the control group. The concentrations of AEA were （0.37±0.07） and （5.67±1.34） ng/mL （P〈0.05）. It is concluded that the expression of endocannabinoids AEA and its cannabinoid receptor CBR were significantly increased in schistosoma-infected mice. Endogenous endocannabinoids may be involved in the development of schistosoma-induced liver fibrosis.     

穴位埋线对免疫抑制大鼠血清T淋巴细胞表面标志CD_4、CD_8及脾脏指数的影响

目的:探讨穴位埋线对免疫抑制大鼠血清T淋巴细胞表面标志CD4、CD8及脾脏指数的作用及机制。方法:取3月龄雄性Wistar大鼠,腹腔注射环磷酰胺造成免疫抑制大鼠模型后,取双侧足三里、三阴交及关元穴行穴位埋线治疗,于治疗28天球后取血测定T淋巴细胞表面标志CD4和CD8的含量及测定脾脏指数。结果:穴位埋线治疗后,免疫抑制大鼠血清T淋巴细胞表面标志CD4和CD8含量明显上升(P0.05)及脾脏指数增高(P0.05)。结论:1穴位埋线可通过提高免疫抑制大鼠血清中T淋巴细胞表面标志CD4和CD8含量从而提高免疫抑制大鼠的细胞免疫能力;2穴位埋线疗法能提高免疫抑制大鼠脾脏指数。     

基于循证医学的中医论治在厥证文献系统评价研究中的应用

神志是机体生长发育及其与外部环境相互作用过程中形成的特殊功能活动,具体表现为感觉、感情、意识、思维、精神、语言、记忆、智力、行为等多种内容［1］。神志病是指在六淫外邪、七情内伤、饮食失节及外伤等各种因素作用下,人体阴阳失调,脏腑功能受扰,气血津液变动,引起脑神功能失常,导致各种神志异常而神志功能活动障碍的一类疾病［2］。厥证是神志病中的常见病证,其内涵有三：①泛指突然昏倒,不省人事,但大多能逐渐苏醒的一类病证。《素问?厥论》有以六经形证立名的巨阳、阳明、少阳、太阴、少阴、厥阴之厥等。历代文献又有寒厥、热厥、蛔厥、尸厥、薄厥、煎厥、痰厥、食厥、气厥、血厥等名称。②指四肢寒冷。③指癃证之危重者［3］。其中气厥、血厥之实证与痰厥,多形体壮实,其发作多与精神刺激密切相关,是中医神志病学研究的内容。气厥实证者,证见突然昏倒,不省人事,口噤拳握,呼吸气粗,或四肢厥冷,舌苔薄白,脉沉或沉弦。血厥实证者,证见突然昏倒,不省人事,牙关紧闭,面赤唇紫,舌红,脉多沉弦。痰厥是素体多湿多痰,复因恼怒气逆,痰随气升上闭清窍而发厥。     

经颅磁刺激治疗帕金森病影响因素的研究进展

帕金森病(Parkinsons disease,PD)属于中枢神经系统常见的变性疾病,其药物治疗存在一定的局限性,而且随着病程进展逐渐衰退,部分患者对多巴胺治疗不能耐受[1].经颅磁刺激(transcranial magnetic stimulation,TMS)是近来用于神经康复治疗的一种技术,不仅可以检测PD患者运动皮层兴奋性,而且可以调节运动皮层的兴奋性,从而改善PD患者的运动功能[2].TMS作为一种无创、无痛、安全的脑刺激手段,已广泛应用于PD的临床治疗中.     

穴位注射结合捏脊疗法治疗阳虚型不寐临床观察

目的：观察穴位注射结合捏脊疗法治疗阳虚型不寐临床疗效。方法：将符合纳入标准的70例患者随机分为3组,治疗组采用刺五加注射液风府穴穴位注射结合捏脊;针刺组采用常规取穴;对照组采用艾司唑仑口服。结果：治疗组总有效率（95.83%）高于针刺组（82.60%）及对照组（78.26%）（P〈0.05）。与本组治疗前比较,三组均可降低PSQI评分（P〈0.05）;与针刺组和对照组治疗后比较,治疗组PSQI评分显著降低,具有统计学差异（P〈0.01）。结论：刺五加注射液风府穴穴位注射结合捏脊疗法能有效改善阳虚失眠患者睡眠状况。     

食管癌组织吲哚胺2,3-双加氧酶1(IDO-1)高表达与食管癌患者不良预后相关

目的 基于多种生物信息学数据库和免疫组织化学染色分析吲哚胺2, 3-双加氧酶1(IDO-1)在食管癌中的表达及临床意义。方法 通过免疫组织化学染色法检测IDO-1在食管癌组织和癌旁组织的表达水平,利用肿瘤免疫评估资源数据库(TIMER)、基因表达谱交互分析数据库(GEPIA)、阿拉巴马大学伯明翰分校癌症数据分析数据库(UALCAN)、 Kaplan-Meier plotter、癌症基因组图谱数据库(TCGA)等数据库分析IDO-1在食管癌组织中的表达情况,IDO-1差异表达对食管癌患者预后的影响,IDO-1表达与肿瘤特征基因通路的相关性,IDO-1表达与免疫细胞浸润情况及免疫检查点表达情况的相关性。结果 免疫组织化学染色结果显示,IDO-1在食管癌组织中的阳性表达率为70%,明显高于癌旁组织的15%;IDO-1表达与患者年龄、性别无显著差异。IDO-1表达在低分化食管癌组织、高临床分期级有淋巴结转移的组织表达增加;GEPIA数据库和TIMER数据库分析结果显示,IDO-1在食管癌组织中表达水平显著高于癌旁组织;UALCAN数据库分析结果显示,IDO-1在低分化食管癌、有淋巴结转移的患者...     

回旋灸联合安普贴外敷治疗老年压力性损伤临床疗效

目的 探讨回旋灸联合安普贴外敷治疗老年压力性损伤患者的临床疗效.方法 选取自2019年1月至2020年12月黑龙江中医药大学附属第二医院收治的50例2期老年压力性损伤患者为研究对象.根据随机数字表法将患者分为单纯治疗组和联合治疗组,每组各25例.两组患者均采用压力性损伤的常规处理,单纯治疗组在伤口处理20 min后给予...     

针刺治疗脑出血研究进展

本研究回顾分析近年来针刺治疗脑出血临床实验文献,综合论述近年来针刺治疗脑出血研究进展。临床研究方面,针刺治疗脑出血方法简便,安全可靠,疗效确切;实验研究方面,多角度、多靶点论述针刺治疗脑出血的作用机理。说明针刺治疗脑出血取得较大的研究进展,体现针刺治疗脑出血的优势。     

针刺治疗躁狂症的国内研究进展

系统回顾近年针刺治疗躁狂症的临床及实验研究文献,阐述近年来针刺治疗躁狂症的研究进展。针刺疗法治疗躁狂症历史悠久,化痰、通经络为针刺治疗躁狂症的基本方法。从临床研究文献可见,针刺治疗躁狂症疗效确切、安全可靠。从作用机制研究得知,针刺疗法可能通过正性调节谷氨酸通路达到治疗躁狂症的目的。近年针刺治疗躁狂症的科学研究取得了一定的成果,展现出针刺疗法治疗躁狂症的优越性。     

Efficacy of Telbivudine in the Treatment of Chronic Hepatitis B and Liver Cirrhosis and Its Effect on Immunological Responses

This study was aimed to evaluate the long-term effects of telbivudine(Ld T) in the treatment of chronic hepatitis B(CHB) and HBV-related liver cirrhosis(LC) and to observe the changes of immunological responses during Ld T treatment. Clinical data of 80 CHB and 28 HBV-related LC patients who were administered with Ld T for 108 weeks and followed up were retrospectively analyzed. The liver function indicators including ALT, AST and γ-GT, HBV DNA copy number in serum and the rates of hepatitis B e antigen(HBe Ag) seroconversion were analyzed before and 12, 24, 36, 48, 60, 72, 84, 96 and 108 weeks after Ld T treatment in CHB and LC groups. Four serum fibrosis-related markers, including hyaluronic acid(HA), human laminin(LN), human type Ⅳ collagen(Ⅳ-C) and human N-terminal procollagen Ⅲ peptide(PC-Ⅲ), were detected before and after Ld T treatment in LC group. The results showed favorable viral suppression and biochemical responses after treatment with Ld T for 12 weeks, and a high rate of virological and biochemical control was maintained during the course of 108-week treatment in both CHB and LC groups. The four fibrosis-related markers, especially HA and LN, were down-regulated to some degrees in LC group. Moreover, Ld T treatment led to the fluctuation of the circulating interferon-γ(IFN-γ) and interleukin-10(IL-10) levels at different time points in CHB group. It was concluded that Ld T could favorably lead to the virological suppression and biochemical remission. Besides, IFN-γ and IL-10 may represent a suitable and effective predictor of responsiveness during Ld T therapy.